Viaderma Inc (VDRM) 0.0025 $VDRM
Timing is Crucial, Upside Analysis - Complementary Research on Viaderma, Imageware Systems, Secom and Brambles
ACCESSWIRE - Thu Mar 10, 9:15AM CST
NEW YORK, NY / ACCESSWIRE / March 10, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Viaderma Inc. (OTC: VDRM), Imageware Systems Inc. (OTC: IWSY), Secom Co. Ltd. (OTC: SOMLY) and Brambles Ltd. (OTC: BXBLY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis
GlobeNewswire - Mon Mar 02, 8:17AM CST
ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.
ViaDerma, Inc. Launches New Website
GlobeNewswire - Tue Jan 13, 8:01AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to the market, is excited to officially announce its new website viadermalicensing.com. The new site features extensive company information that has been carefully revamped in preparation for increased marketing, sales and distribution efforts which will be a focus in 2015.
TetraStem(TM) Antibiotic Continues to Demonstrate Treatment Success Leading Management to Explore Partnerships With Big Pharmaceutical Companies
GlobeNewswire - Tue Dec 09, 8:44AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced TetraStem, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.'
ViaDerma, Inc. Lead Product TetraStem Shows Promise in Treating Acne
GlobeNewswire - Fri Nov 21, 9:16AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery method to apply almost any active ingredient to a topical drug. It has recently shown promising results for acne sufferers with the minimal side effects that are usually associated with other medications.
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board
GlobeNewswire - Thu Nov 13, 10:26AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is pleased to announce the appointment of Dr. Andrew Berman as the Medical Director of the advisory board.
TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations
GlobeNewswire - Fri Nov 07, 7:54AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.
These Small-Cap Marijuana Stocks are in Play Next Week
ACCESSWIRE - Fri Oct 31, 11:35AM CDT
Coral Gables, FL / ACCESSWIRE / October 31, 2014 / ViaDerma, Inc. (OTCQB: VDRM) ecently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA
PR Newswire - Thu Oct 30, 7:00AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015
PR Newswire - Wed Oct 29, 2:26PM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is committed to pursuing out-licensing partnerships in 2015.
Timing is Crucial, Upside Analysis - Complementary Research on Viaderma, Imageware Systems, Secom and Brambles
ACCESSWIRE - Thu Mar 10, 9:15AM CST
NEW YORK, NY / ACCESSWIRE / March 10, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Viaderma Inc. (OTC: VDRM), Imageware Systems Inc. (OTC: IWSY), Secom Co. Ltd. (OTC: SOMLY) and Brambles Ltd. (OTC: BXBLY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis
GlobeNewswire - Mon Mar 02, 8:17AM CST
ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.
ViaDerma, Inc. Launches New Website
GlobeNewswire - Tue Jan 13, 8:01AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to the market, is excited to officially announce its new website viadermalicensing.com. The new site features extensive company information that has been carefully revamped in preparation for increased marketing, sales and distribution efforts which will be a focus in 2015.
TetraStem(TM) Antibiotic Continues to Demonstrate Treatment Success Leading Management to Explore Partnerships With Big Pharmaceutical Companies
GlobeNewswire - Tue Dec 09, 8:44AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced TetraStem, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.'
ViaDerma, Inc. Lead Product TetraStem Shows Promise in Treating Acne
GlobeNewswire - Fri Nov 21, 9:16AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery method to apply almost any active ingredient to a topical drug. It has recently shown promising results for acne sufferers with the minimal side effects that are usually associated with other medications.
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board
GlobeNewswire - Thu Nov 13, 10:26AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is pleased to announce the appointment of Dr. Andrew Berman as the Medical Director of the advisory board.
TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations
GlobeNewswire - Fri Nov 07, 7:54AM CST
ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.
These Small-Cap Marijuana Stocks are in Play Next Week
ACCESSWIRE - Fri Oct 31, 11:35AM CDT
Coral Gables, FL / ACCESSWIRE / October 31, 2014 / ViaDerma, Inc. (OTCQB: VDRM) ecently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA
PR Newswire - Thu Oct 30, 7:00AM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015
PR Newswire - Wed Oct 29, 2:26PM CDT
ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is committed to pursuing out-licensing partnerships in 2015.
